Proof of concept of triple COMBI therapy to prohibit MPN progression to AML

Hans Carl Hasselbalch; Vibe Skov; Lasse Kjaer; Morten Kranker Larsen

doi:10.1111/bjh.19173

Proof of concept of triple COMBI therapy to prohibit MPN progression to AML

Br J Haematol. 2024 Jan;204(1):16-18. doi: 10.1111/bjh.19173. Epub 2023 Nov 13.

Authors

Hans Carl Hasselbalch¹, Vibe Skov¹, Lasse Kjaer¹, Morten Kranker Larsen¹

Affiliation

¹ Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

PMID: 37957927
DOI: 10.1111/bjh.19173

Abstract

Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on: Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2024;204:206-220.

Keywords: AML; prohibit MPN progression; triple COMBI therapy.

Publication types

Comment

MeSH terms

Azacitidine / therapeutic use
Humans
Interferons / therapeutic use
Leukemia, Myeloid, Acute* / drug therapy
Myeloproliferative Disorders* / drug therapy
Prognosis

Substances

Azacitidine
Interferons